Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study

被引：6
作者：
Sgouros J. [1 ]
Aravantinos G. [2 ]
Kouvatseas G. [3 ]
Rapti A. [1 ]
Stamoulis G. [1 ]
Bisvikis A. [1 ]
Res H. [1 ]
Samantas E. [1 ]
机构：
[1] 3rd Medical Oncology Department, “Agii Anargiri” General Cancer Hospital, Kaliftaki, N. Kifissia
[2] 2nd Medical Oncology Department, “Agii Anargiri” General Cancer Hospital, Kaliftaki, N. Kifissia
[3] Health Data Specialists, Ltd, 22 Katehaki Str, Athens
来源：
Journal of Gastrointestinal Cancer | 2015年 / 46卷 / 4期
关键词：
Adjuvant chemotherapy; Colorectal cancer; Delays between chemotherapy cycles; Dose reductions; Omission of chemotherapy cycles;
D O I：
10.1007/s12029-015-9746-8
中图分类号：
学科分类号：
摘要：
Purpose: Most stage II or III colorectal cancer patients are receiving nowadays a 4 to 6-month course of adjuvant chemotherapy. However, delays between cycles, reductions in the doses of chemotherapy drugs, or even permanent omissions of chemotherapy cycles might take place due to side effects or patient’s preference. We examined the impact of these treatment modifications on recurrence-free survival (RFS) and overall survival (OS). Methods: We retrospectively collected data from colorectal cancer patients who had received adjuvant chemotherapy in our Department. Patients were categorized in five groups based on whether they had or not delays between chemotherapy cycles, dose reductions, and permanent omissions of chemotherapy cycles. Three-year RFS and OS of the five different groups were compared using the log-rank test and the Sidak approach. Results: Five hundred and eight patients received treatment. Twenty seven percent of the patients had the full course of chemotherapy; the others had delays, dose reductions, or early termination of the treatment. No statistically significant differences were observed in 3-year RFS and OS between the five groups. A trend for worse RFS was noticed with early termination of treatment. A similar trend was also noticed for OS but only for stage II patients. Conclusion: In colorectal cancer patients, receiving adjuvant chemotherapy, delays between chemotherapy cycles, dose reductions of chemotherapy drugs, or even early termination of the treatment course do not seem to have a negative impact in 3-year RFS and OS; however, due to the trend of worse RFS in patients receiving shorter courses of chemotherapy, further studies are needed. © 2015, Springer Science+Business Media New York.
引用
收藏
页码：343 / 349
页数：6
相关论文
共 23 条
  • [1] Minicozzi P., Kaleci S., Maffei S., Allemani C., Giacomin A., Caldarella A., Et al., Disease presentation, treatment and survival for Italian colorectal cancer patients: a EUROCARE high resolution study, Eur J Pub Health, 24, pp. 98-100, (2014)
  • [2] Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Goodman P.J., Et al., Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma, N Engl J Med, 322, pp. 352-358, (1990)
  • [3] O'Connell M.J., Mailliard J.A., Kahn M.J., Macdonald J.S., Haller D.G., Mayer R.J., Et al., Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer, J Clin Oncol, 15, pp. 246-250, (1997)
  • [4] O'Connor E.S., Greenblatt D.Y., LoConte N.K., Gangnon R.E., Liou J.I., Heise C.P., Et al., Adjuvant chemotherapy for stage II colon cancer with poor prognostic features, J Clin Oncol, 29, pp. 3381-3388, (2011)
  • [5] Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer, J Clin Oncol, 17, pp. 1356-1363, (1999)
  • [6] Bosset J.F., Calais G., Mineur L., Maingon P., Stojanovic-Rundic S., Bensadoun R.J., Et al., Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study, Lancet Oncol, 15, pp. 184-190, (2014)
  • [7] Glynne-Jones R., Counsell N., Quirke P., Mortensen N., Maraveyas A., Meadows H.M., Et al., Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control, Ann Oncol, 25, pp. 1356-1362, (2014)
  • [8] Schmoll H.J., Van Cutsem E., Stein A., Valentini V., Glimelius B., Haustermans K., Et al., ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making, Ann Oncol, 23, pp. 2479-2516, (2012)
  • [9] Haller D.G., Tabernero J., Maroun J., de Braud F., Price T., Van Cutsem E., Et al., Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer, J Clin Oncol, 29, pp. 1465-1471, (2011)
  • [10] Pectasides D., Karavasilis V., Papaxoinis G., Gourgioti G., Makatsoris T., Raptou G., Et al., Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer, BMC Cancer, 15, (2015)
123